Zoneddy Dayao

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Matthew J. Ellis, Vera J. Suman, Jeremy Hoog et al. · Journal of Clinical Oncology · 2017 · 411 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Neelima Denduluri, Mark R. Somerfield, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2020 · 101 citations

Medicine, Oncology, Breast Oncology +16

Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105

Dawn L. Hershman, Joseph M. Unger, Grace Clarke Hillyer et al. · Journal of Clinical Oncology · 2020 · 79 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Harold J. Burstein, Angela DeMichele, Lesley Fallowfield et al. · Journal of Clinical Oncology · 2024 · 48 citations · Full text

Medicine, Endocrinology, Oncology +15